The P2X7 receptor: A key player in immune-mediated bone loss?

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Kvist, Torben Madsen ^a   Schwarz, Peter ^a,b   Jørgensen, Niklas Rye ^a,b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PURINERGIC P2X7 RECEPTOR;

ANIMAL; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; OSTEOPOROSIS;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; OSTEOPOROSIS; RECEPTORS, PURINERGIC P2X7;

EID: 84893836930     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/954530     Document Type: Review

References (123)

1. Crowson C. S., Matteson E. L., Myasoedova E., Michet C. J., Ernste F. C., Warrington K. J., Davis J. M. III, Hunder G. G., Therneau T. M., Gabriel S. E., The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis and Rheumatism 2011 63 3 633 639 2-s2.0-79953707617 10.1002/art.30155
2. Goldring S. R., Gravallese E. M., Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Research 2000 2 1 33 37 2-s2.0-0034469421 10.1186/ar67 (Pubitemid 32223681)
3. Goldring S. R., Schett G., Lorenzo J., Choi Y., Horowitz M., Takayanagi H., The role of the immune system in the bone loss of inflammatory arthritis. Osteoimmunology 2011 London, UK Academic Press 301 324 10.1016/B978-0-12-375670- 1.10010-X
4. Güler-Yüksel M., Bijsterbosch J., Goekoop-Ruiterman Y. P. M., De Vries-Bouwstra J. K., Ronday H. K., Peeters A. J., De Jonge-Bok J. M., Breedveld F. C., Dijkmans B. A. C., Allaart C. F., Lems W. F., Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 11 1508 1512 2-s2.0-35649001540 10.1136/ard.2007.070839 (Pubitemid 350032661)
5. Mundy G. R., Osteoporosis and inflammation. Nutrition reviews 2007 65 12 S147 S151 2-s2.0-39649106601
6. Schett G., David J. P., The multiple faces of autoimmune-mediated bone loss. Nature Reviews Endocrinology 2010 6 12 698 706 2-s2.0-78649447658 10.1038/nrendo.2010.190
7. Andreassen H., Rungby J., Dahlerup J. F., Mosekilde L., Inflammatory bowel disease and osteoporosis. Scandinavian Journal of Gastroenterology 1997 32 12 1247 1255 2-s2.0-0031452096 (Pubitemid 28023130)
8. Bernstein C. N., Leslie W. D., Review article: osteoporosis and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2004 19 9 941 952 2-s2.0-2442712481 10.1111/j.1365-2036.2004.01876.x (Pubitemid 38657375)
9. Jørgensen N. R., Schwarz P., Holme I., Henriksen B. M., Petersen L. J., Backer V., The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease-a cross sectional study. Respiratory Medicine 2007 101 1 177 185 2-s2.0-33751531953 10.1016/j.rmed.2006.03.029 (Pubitemid 44835231)
10. Hardy R., Cooper M. S., Bone loss in inflammatory disorders. Journal of Endocrinology 2009 201 3 309 320 2-s2.0-67849119581 10.1677/JOE-08-0568
11. Armour K. J., Armour K. E., Inflammation-induced osteoporosis. The IMO model. Methods in Molecular Medicine 2003 80 353 360 10.1385/1-59259-366-6:353 2-s2.0-0038049129
12. Armour K. J., Armour K. E., van't Hof R. J., Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheumatism 2001 44 2790 2796 (Pubitemid 34016198)
13. Armour K. E., Van 'T Hof R. J., Grabowski P. S., Reid D. M., Ralston S. H., Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. Journal of Bone and Mineral Research 1999 14 12 2137 2142 2-s2.0-0033392377 (Pubitemid 30026963)
14. Alnaeeli M., Teng Y. T. A., Dendritic cells: a new player in osteoimmunology. Current Molecular Medicine 2009 9 7 893 910 2-s2.0-70350522009 10.2174/156652409789105507
15. Bar-Shavit Z., The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. Journal of Cellular Biochemistry 2007 102 5 1130 1139 2-s2.0-36849051963 10.1002/jcb.21553 (Pubitemid 350220034)
16. David J. P., Osteoimmunology: a view from the bone. Advances in Immunology 2007 95 149 165 2-s2.0-34548494841 10.1016/S0065-2776(07)95005-1 (Pubitemid 47380505)
17. Barnabe C., Hanley D. A., Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Seminars in Arthritis and Rheumatism 2009 39 2 116 122 2-s2.0-70349454163 10.1016/j.semarthrit.2008.04.004
18. Di Virgilio F., Liaisons dangereuses: P2X7 and the inflammasome. Trends in Pharmacological Sciences 2007 28 9 465 472 2-s2.0-34548444551 10.1016/j.tips.2007.07.002 (Pubitemid 47368700)
19. Trautmann A., Extracellular ATP in the immune system: more than just a 'danger signal'. Science Signaling 2009 2 56, article pe6 2-s2.0-62349114041 10.1126/scisignal.256pe6
20. La Sala A., Ferrari D., Di Virgilio F., Idzko M., Norgauer J., Girolomoni G., Alerting and tuning the immune response by extracellular nucleotides. Journal of Leukocyte Biology 2003 73 3 339 343 2-s2.0-0038823523 10.1189/jlb.0802418 (Pubitemid 36790849)
21. Wesselius A., Bours M. J. L., Agrawal A., Gartland A., Dagnelie P. C., Schwarz P., Jorgensen N. R., Role of purinergic receptor polymorphisms in human bone. Frontiers in Bioscience 2011 16 7 2572 2585 2-s2.0-79959546453 10.2741/3873
22. Pellegatti P., Falzoni S., Pinton P., Rizzuto R., Di Virgilio F., A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Molecular Biology of the Cell 2005 16 8 3659 3665 2-s2.0-23044473247 10.1091/mbc.E05-03-0222 (Pubitemid 41077076)
23. Pellegatti P., Raffaghello L., Bianchi G., Piccardi F., Pistoia V., Di Virgilio F., Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 2008 3 7 2-s2.0-50249085890 10.1371/journal.pone.0002599 e2599
24. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R. M., Curti A., Idzko M., Panther E., Di Virgilio F., The P2X7 receptor: a key player in IL-1 processing and release. Journal of Immunology 2006 176 3877 3883 2-s2.0-59849106548 (Pubitemid 44264361)
25. Ferrari D., Chiozzi P., Falzoni S., Dal Susino M., Melchiorri L., Baricordi O. R., Di Virgilio F., Extracellular ATP triggers IL-1 β release by activating the purinergic P2Z receptor of human macrophages. Journal of Immunology 1997 159 3 1451 1458 2-s2.0-0031201476 (Pubitemid 127484125)
26. Pelegrin P., Barroso-Gutierrez C., Surprenant A., P2X7 receptor differentially couples to distinct release pathways for IL-1 β in mouse macrophage. Journal of Immunology 2008 180 11 7147 7157 2-s2.0-47249144272
27. Perregaux D., Gabel C. A., Interleukin-1 β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. Journal of Biological Chemistry 1994 269 21 15195 15203 2-s2.0-0028175838
28. Labasi J. M., Petrushova N., Donovan C., McCurdy S., Lira P., Payette M. M., Brissette W., Wicks J. R., Audoly L., Gabel C. A., Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. Journal of Immunology 2002 168 12 6436 6445 2-s2.0-0037096207 (Pubitemid 34620068)
29. Ichinose M., Modulation of phagocytosis by P2-purinergic receptors in mouse peritoneal macrophages. Japanese Journal of Physiology 1995 45 5 707 721 2-s2.0-0029176686 (Pubitemid 3011653)
30. Hanley P. J., Kronlage M., Kirschning C., Transient P2X7 receptor activation triggers macrophage death independent of Toll-like receptors 2 and 4, caspase-1, and pannexin-1 proteins. Journal of Biological Chemistry 2012 287 13 10650 10663 10.1074/jbc.M111.332676
31. Lemaire I., Falzoni S., Zhang B., Pellegatti P., Di Virgilio F., The P2X7 receptor and pannexin-1 are both required for the promotion of multinucleated macrophages by the inflammatory cytokine GM-CSF. Journal of Immunology 2011 187 7 3878 3887 2-s2.0-80053475754 10.4049/jimmunol.1002780
32. Pellegatti P., Falzoni S., Donvito G., Lemaire I., Di Virgilio F., P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB Journal 2011 25 4 1264 1274 2-s2.0-79954583662 10.1096/fj.10-169854
33. Lopez-Castejon G., Theaker J., Pelegrin P., Clifton A. D., Braddock M., Surprenant A., P2X7 receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. Journal of Immunology 2010 185 4 2611 2619 2-s2.0-77956936562 10.4049/jimmunol.1000436
34. Guerra A. N., Fisette P. L., Pfeiffer Z. A., Quinchia-Rios B. H., Prabhu U., Aga M., Denlinger L. C., Guadarrama A. G., Abozeid S., Sommer J. A., Proctor R. A., Bertics P. J., Purinergic receptor regulation of LPS-induced signaling and pathophysiology. Journal of Endotoxin Research 2003 9 4 256 263 2-s2.0-10744223451 10.1179/096805103225001468 (Pubitemid 36874537)
35. Sluyter R., Wiley J. S., Extracellular adenosine 5′-triphosphate induces a loss of CD23 from human dendritic cells via activation of P2X7 receptors. International Immunology 2002 14 12 1415 1421 2-s2.0-0036910307 10.1093/intimm/dxf111 (Pubitemid 36024607)
36. Ferrari D., La Sala A., Chiozzi P., Morelli A., Falzoni S., Girolomoni G., Idzko M., Dichmann S., Norgauer J., Di Virgilio F., The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB Journal 2000 14 15 2466 2476 2-s2.0-0033669308
37. Sluyter R., Wiley J. S., Extracellular adenosine 5′-triphosphate induces a loss of CD23 from human dendritic cells via activation of P2X7 receptors. International Immunology 2002 14 12 1415 1421 2-s2.0-0036910307 10.1093/intimm/dxf111 (Pubitemid 36024607)
38. Ferrari D., La Sala A., Chiozzi P., Morelli A., Falzoni S., Girolomoni G., Idzko M., Dichmann S., Norgauer J., Di Virgilio F., The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB Journal 2000 14 15 2466 2476 2-s2.0-0033669308
39. Labasi J. M., Petrushova N., Donovan C., McCurdy S., Lira P., Payette M. M., Brissette W., Wicks J. R., Audoly L., Gabel C. A., Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. Journal of Immunology 2002 168 12 6436 6445 2-s2.0-0037096207 (Pubitemid 34620068)
40. Budagian V., Bulanova E., Brovko L., Orinska Z., Fayad R., Paus R., Bulfone-Paus S., Signaling through P2X7 receptor in human T cells involves p56lck MAP kinases, and transcription factors AP-1 and NF- B. Journal of Biological Chemistry 2003 278 3 1549 1560 2-s2.0-0037449706 10.1074/jbc. M206383200 (Pubitemid 36801383)
41. Bours M. J. L., Swennen E. L. R., Di Virgilio F., Cronstein B. N., Dagnelie P. C., Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacology and Therapeutics 2006 112 2 358 404 2-s2.0-33749261659 10.1016/j.pharmthera.2005.04.013 (Pubitemid 44486409)
42. Buckley K. A., Golding S. L., Rice J. M., Dillon J. P., Gallagher J. A., Release and interconversion of P2 receptor agonists by human osteoblast-like cells. FASEB Journal 2003 17 11 1401 1410 2-s2.0-0041709201 10.1096/fj.02- 0940com (Pubitemid 36935655)
43. Grol M. W., Zelner I., Dixon S. J., P2X7-mediated calcium influx triggers a sustained, PI3K-dependent increase in metabolic acid production by osteoblast-like cells. American Journal of Physiology-Endocrinology and Metabolism 2012 302 5 E561 E575 2-s2.0-84857241763 10.1152/ajpendo.00209.2011
44. 2+- and ATP-dependent in MC3T3-E1 osteoblasts. Bone 2008 42 4 644 652 2-s2.0-40849111180 10.1016/j.bone.2007.09.058
45. Matsuo K., Ray N., Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. Keio Journal of Medicine 2004 53 2 78 84 2-s2.0-3142592253 10.2302/kjm.53.78 (Pubitemid 38899740)
46. Okumura H., Shiba D., Kubo T., Yokoyama T., P2X7 receptor as sensitive flow sensor for ERK activation in osteoblasts. Biochemical and Biophysical Research Communications 2008 372 3 486 490 2-s2.0-44749083240 10.1016/j.bbrc.2008.05.066
47. Panupinthu N., Zhao L., Possmayer F., Ke H. Z., Sims S. M., Dixon S. J., P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. Journal of Biological Chemistry 2007 282 5 3403 3412 2-s2.0-34047243995 10.1074/jbc.M605620200 (Pubitemid 47084361)
48. Gartland A., Hipskind R. A., Gallagher J. A., Bowler W. B., Expression of a P2X7 receptor by a subpopulation of human osteoblasts. Journal of Bone and Mineral Research 2001 16 5 846 856 2-s2.0-0034744672 (Pubitemid 32332294)
49. Panupinthu N., Rogers J. T., Zhao L., Solano-Flores L. P., Possmayer F., Sims S. M., Dixon S. J., P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. Journal of Cell Biology 2008 181 5 859 871 2-s2.0-44649092795 10.1083/jcb.200708037 (Pubitemid 351786989)
50. Orriss I. R., Key M. L., Brandao-Burch A., The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: the role of p2x receptors. Bone 2012 51 389 400 10.1016/j.bone.2012.06.013
51. Li J., Liu D., Ke H. Z., Duncan R. L., Turner C. H., The P2X7 nucleotide receptor mediates skeletal mechanotransduction. Journal of Biological Chemistry 2005 280 52 42952 42959 2-s2.0-30044443068 10.1074/jbc.M506415200 (Pubitemid 43049258)
52. Brandao-Burch A., Key M. L., Patel J. J., The P2X7 receptor is an important regulator of extracellular ATP levels. Frontiers in Endocrinology 2012 3 article 41 10.3389/fendo.2012.00041
53. Orriss I. R., Knight G. E., Utting J. C., Taylor S. E. B., Burnstock G., Arnett T. R., Hransient exposure to hypoxia stimulates ATP release from osteoblasts. Journal of Cellular Physiology 2004 220 1 155 162 2-s2.0-65549133193 10.1002/jcp.21745
54. Genetos D. C., Karin N. J., Geist D. J., Donahue H. J., Duncan R. L., Purinergic signaling is required for fluid shear stress-induced NF- B translocation in osteoblasts. Experimental Cell Research 2011 317 6 737 744 2-s2.0-79952185077 10.1016/j.yexcr.2011.01.007
55. Gabel C. A., P2 purinergic receptor modulation of cytokine production. Purinergic Signalling 2007 3 1-2 27 38 2-s2.0-33947675761 10.1007/s11302-006- 9034-y
56. Penolazzi L., Bianchini E., Lambertini E., Baraldi P. G., Romagnoli R., Piva R., Gambari R., N-Arylpiperazine modified analogues of the P2X7 receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts. Journal of Biomedical Science 2005 12 6 1013 1020 2-s2.0-30544443360 10.1007/s11373-005-9029-7 (Pubitemid 43081680)
57. Korcok J., Raimundo L. N., Ke H. Z., Sims S. M., Dixon S. J., Extracellular nucleotides act through P2X7 receptors to activate NF- B in osteoclasts. Journal of Bone and Mineral Research 2004 19 4 642 651 2-s2.0-3242673859 10.1359/JBMR.040108 (Pubitemid 41071225)
58. Jørgensen N. R., Short-range intercellular calcium signaling in bone. APMIS, Supplement 2005 113 118 1 36 2-s2.0-27744608522 (Pubitemid 41586021)
59. Brandao-Burch A., Burnstock G., Arnett T., Orriss I., The P2X7 receptor is an important regulator of extracellular ATP levels. Frontiers in Endocrinology 2011 3 article 41 10.3389/fendo.2012.00041
60. Steinberg T. H., Hiken J. F., P2 receptors in macrophage fusion and osteoclast formation. Purinergic Signalling 2007 3 1-2 53 57 2-s2.0-33947668825 10.1007/s11302-006-9036-9
61. Gartland A., Buckley K. A., Hipskind R. A., Perry M. J., Tobias J. H., Buell G., Chessell I., Bowler W. B., Gallagher J. A., Multinucleated osteoclast formation in vivo and in vitro by P2X 7 receptor-deficient mice. Critical Reviews in Eukaryotic Gene Expression 2003 13 2-4 243 253 2-s2.0-0346245902 10.1615/CritRevEukaryotGeneExpr.v13.i24.150 (Pubitemid 38009173)
62. Gartland A., Buckley K. A., Hipskind R. A., Bowler W. B., Gallagher J. A., P2 receptors in bone-modulation of osteoclast formation and activity via P2X7 activation. Critical Reviews in Eukaryotic Gene Expression 2003 13 2-4 237 242 2-s2.0-0345732699 10.1615/CritRevEukaryotGeneExpr.v13.i24.140 (Pubitemid 38009172)
63. Collo G., Neidhart S., Kawashima E., Kosco-Vilbois M., North R. A., Buell G., Tissue distribution of the P2X7 receptor. Neuropharmacology 1997 36 9 1277 1283 2-s2.0-0030609068 10.1016/S0028-3908(97)00140-8 (Pubitemid 27465615)
64. Burnstock G., Knight G. E., Cellular distribution and functions of P2 receptor subtypes in different systems. International Review of Cytology 2004 240 31 304 2-s2.0-9144269934 10.1016/S0074-7696(04)40002-3 (Pubitemid 39539202)
65. Gu B. J., Zhang W. Y., Bendall L. J., Chessell I. P., Buell G. N., Wiley J. S., Expression of P2X7 purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X7 receptors. American Journal of Physiology-Cell Physiology 2000 279 4 C1189 C1197 2-s2.0-0033711728
66. Mariathasan S., Hewton K., Monack D. M., Vucic D., French D. M., Lee W. P., Roose-Girma M., Erickson S., Dixit V. M., Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004 430 6996 213 218 2-s2.0-3142654767 10.1038/nature02664 (Pubitemid 38902430)
67. Kahlenberg J. M., Dubyak G. R., Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. American Journal of Physiology-Cell Physiology 2004 286 5 C1100 C1108 2-s2.0-1942422683 10.1152/ajpcell.00494.2003 (Pubitemid 38506925)
68. Kahlenberg J. M., Lundberg K. C., Kertesy S. B., Qu Y., Dubyak G. R., Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF- B-driven protein synthesis. Journal of Immunology 2005 175 11 7611 7622 2-s2.0-28244459680 (Pubitemid 41713461)
69. Dubyak G. R., P2X7 receptor regulation of non-classical secretion from immune effector cells. Cellular Microbiology 2012 14 1697 1706 10.1111/cmi.12001
70. Pelegrin P., Surprenant A., Pannexin-1 mediates large pore formation and interleukin-1 β release by the ATP-gated P2X7 receptor. EMBO Journal 2006 25 21 5071 5082 2-s2.0-33750473352 10.1038/sj.emboj.7601378 (Pubitemid 44658525)
71. Tonetti M., Sturla L., Giovine M., Benatti U., De Flora A., Extracellular ATP enhances mRNA levels of nitric oxide synthase and TNF-in lipopolysaccharide-treated raw 264.7 murine macrophages. Biochemical and Biophysical Research Communications 1995 214 1 125 130 2-s2.0-0029160229 10.1006/bbrc.1995.2265
72. Denlinger L. C., Angelini G., Schell K., Green D. N., Guadarrama A. G., Prabhu U., Coursin D. B., Bertics P. J., Hogan K., Detection of human P2X7 nucleotide receptor polymorphisms by a novel monocyte pore assay predictive of alterations in lipopolysaccharide-induced cytokine production. Journal of Immunology 2005 174 7 4424 4431 2-s2.0-15444364434 (Pubitemid 40396026)
73. Grol M. W., Panupinthu N., Korcok J., Sims S. M., Dixon S. J., Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signalling 2009 5 2 205 221 2-s2.0-67349186489 10.1007/s11302-009-9139-1
74. Henriksen Z., Hiken J. F., Steinberg T. H., Jørgensen N. R., The predominant mechanism of intercellular calcium wave propagation changes during long-term culture of human osteoblast-like cells. Cell Calcium 2006 39 5 435 444 2-s2.0-33645221301 10.1016/j.ceca.2006.01.012
75. Jørgensen N. R., Henriksen Z., Sørensen O. H., Eriksen E. F., Civitelli R., Steinberg T. H., Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. Journal of Biological Chemistry 2002 277 9 7574 7580 2-s2.0-0036510537 10.1074/jbc.M104608200 (Pubitemid 34953156)
76. Solgaard M., Jørgensen N. R., P2 purinergic receptors: their regulation of bone metabolism and their therapeutic potential. Ugeskrift for Laeger 2005 167 34 3152 3156 2-s2.0-23844548402 (Pubitemid 41321244)
77. Jørgensen N. R., Geist S. T., Civitelli R., Steinberg T. H., ATP- and gap junction-dependent intercellular calcium signaling in osteoblastic cells. Journal of Cell Biology 1997 139 2 497 506 2-s2.0-0030776894 10.1083/jcb.139.2.497 (Pubitemid 27459320)
78. Jørgensen N. R., Henriksen Z., Brot C., Eriksen E. F., Sørensen O. H., Civitelli R., Steinberg T. H., Human osteoblastic cells propagate intercellular calcium signals by two different mechanisms. Journal of Bone and Mineral Research 2000 15 6 1024 1032 2-s2.0-0034120397 (Pubitemid 30350065)
79. Jørgensen N. R., Teilmann S. C., Henriksen Z., Civitelli R., Sørensen O. H., Steinberg T. H., Activation of L-type calcium channels is required for gap junction-mediated intercellular calcium signaling in osteoblastic cells. Journal of Biological Chemistry 2003 278 6 4082 4086 2-s2.0-0038787824 10.1074/jbc.M205880200 (Pubitemid 36801143)
80. Kringelbach T., Novak I., Bonewald L., UTP and mechanical stimulation induce ATP release from osteocytes. Bone 2012 50 supplement 1 S95 10.1016/j.bone.2012.02.285
81. Gallagher J. A., Buckley K. A., Expression and function of P2 receptors in bone. Journal of Musculoskeletal Neuronal Interactions 2002 2 5 432 439 2-s2.0-0036715399 (Pubitemid 35023620)
82. Gallagher J. A., ATP P2 receptors and regulation of bone effector cells. Journal of Musculoskeletal Neuronal Interactions 2004 4 2 125 127 2-s2.0-3042856490 (Pubitemid 38877760)
83. Orriss I. R., Key M. L., Brandao-Burch A., The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: the role of p2x receptors. Bone 2012 51 389 400 10.1016/j.bone.2012.06.013
84. Genetos D. C., Geist D. J., Liu D., Donahue H. J., Duncan R. L., Fluid shear-induced ATP secretion mediates prostaglandin release in MC3T3-E1 osteoblasts. Journal of Bone and Mineral Research 2005 20 1 41 49 2-s2.0-21644466461 10.1359/jbmr.2005.20.1.41 (Pubitemid 41716217)
85. Gartland A., Buckley K. A., Hipskind R. A., Perry M. J., Tobias J. H., Buell G., Chessell I., Bowler W. B., Gallagher J. A., Multinucleated osteoclast formation in vivo and in vitro by P2X 7 receptor-deficient mice. Critical Reviews in Eukaryotic Gene Expression 2003 13 2-4 243 253 2-s2.0-0346245902 10.1615/CritRevEukaryotGeneExpr.v13.i24.150 (Pubitemid 38009173)
86. 2+- and ATP-dependent in MC3T3-E1 osteoblasts. Bone 2008 42 4 644 652 2-s2.0-40849111180 10.1016/j.bone.2007.09.058
87. Panupinthu N., Zhao L., Possmayer F., Ke H. Z., Sims S. M., Dixon S. J., P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. Journal of Biological Chemistry 2007 282 5 3403 3412 2-s2.0-34047243995 10.1074/jbc.M605620200 (Pubitemid 47084361)
88. Kringelbach T., Schwarz P., Novak I., P2 receptors are functionally expressed in MLO-Y4 osteocytes. Purinergic Signalling 2008 4 173 174
89. Li J., Liu D., Ke H. Z., Duncan R. L., Turner C. H., The P2X7 nucleotide receptor mediates skeletal mechanotransduction. Journal of Biological Chemistry 2005 280 52 42952 42959 2-s2.0-30044443068 10.1074/jbc.M506415200 (Pubitemid 43049258)
90. Kringelbach T., Novak I., Schwarz P., Jørgensen N. R., Nucleotide and mechanically induced ATP release pathways in osteocytes. Bone Abstracts 2013 1 237 10.1530/boneabs.1.PP237
91. Brandao-Burch A., Key M. L., Patel J. J., The P2X7 receptor is an important regulator of extracellular ATP levels. Frontiers in Endocrinology 2012 3 article 41 10.3389/fendo.2012.00041
92. Takayanagi H., Mechanistic insight into osteoclast differentiation in osteoimmunology. Journal of Molecular Medicine 2005 83 3 170 179 2-s2.0-16844377831 10.1007/s00109-004-0612-6 (Pubitemid 40487405)
93. Arbor A., Inhibition of osteoblast functions by IKK/NF- B in osteoporosis. Nature Medicine 2009 15 6 682 689 10.1038/nm.1954
94. Tak P. P., Firestein G. S., NF- B: a key role in inflammatory diseases. Journal of Clinical Investigation 2001 107 1 7 11 2-s2.0-0034746919
95. Marcus R., Feldman D., Nelson D., Rosen C., Fundamentals of Osteoporosis 2009
96. Grol M. W., Zelner I., Jeffrey Dixon S., P2X7-mediated calcium influx triggers a sustained, PI3K-dependent increase in metabolic acid production by osteoblast-like cells. American Journal of Physiology-Endocrinology and Metabolism 2012 302 5 E561 E575 2-s2.0-84857241763 10.1152/ajpendo.00209.2011
97. Ke H. Z., Qi H., Weidema A. F., Zhang Q., Panupinthu N., Crawford D. T., Grasser W. A., Paralkar V. M., Li M., Audoly L. P., Gabel C. A., Jee W. S. S., Dixon S. J., Sims S. M., Thompson D. D., Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Molecular Endocrinology 2003 17 7 1356 1367 2-s2.0-0037634326 10.1210/me.2003-0021 (Pubitemid 36819956)
98. Gu B. J., Wiley J. S., Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 2006 107 12 4946 4953 2-s2.0-33745088086 10.1182/blood-2005-07-2994 (Pubitemid 43882649)
99. Jelassi B., Chantme A., Alcaraz-Pérez F., Baroja-Mazo A., Cayuela M. L., Pelegrin P., Surprenant A., Roger S., P2X 7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 2011 30 18 2108 2122 2-s2.0-79955579562 10.1038/onc.2010.593
100. Solle M., Labasi J., Perregaux D. G., Stam E., Petrushova N., Koller B. H., Griffiths R. J., Gabel C. A., Altered cytokine production in mice lacking P2X7 receptors. Journal of Biological Chemistry 2001 276 1 125 132 2-s2.0-0035808396 10.1074/jbc.M006781200 (Pubitemid 32050297)
101. Xu X., Boumechache M., Splice-variants of the P2X7 receptor reveal differential agonist-dependence and functional coupling with pannexin-1. Journal of Cell Science 2012 125 3776 3789 10.1242/jcs.099374
102. Nicke A., Kuan Y. H., Masin M., Rettinger J., Marquez-Klaka B., Bender O., Górecki D. C., Murrell-Lagnado R. D., Soto F., A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. Journal of Biological Chemistry 2009 284 38 25813 25822 2-s2.0-70350012258 10.1074/jbc.M109.033134
103. Cheewatrakoolpong B., Gilchrest H., Anthes J. C., Greenfeder S., Identification and characterization of splice variants of the human P2X7 ATP channel. Biochemical and Biophysical Research Communications 2005 332 1 17 27 2-s2.0-19344369446 10.1016/j.bbrc.2005.04.087 (Pubitemid 40719451)
104. Masin M., Young C., Lim K., Barnes S. J., Xu X. J., Marschall V., Brutkowski W., Mooney E. R., Gorecki D. C., Murrell-Lagnado R., Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. British Journal of Pharmacology 2012 165 4 978 993 2-s2.0-84856296099 10.1111/j.1476-5381.2011.01624.x
105. Syberg S., Petersen S., Beck Jensen J. E., Genetic background strongly influences the bone phenotype of P2X7 receptor knockout mice. Journal of Osteoporosis 2012 2012 2012 9 391097 10.1155/2012/391097
106. Syberg S., Schwarz P., Petersen S., Association between P2X7 receptor polymorphisms and bone status in mice. JournAl of Osteoporosis 2012 2012 10 637986 10.1155/2012/637986
107. Orriss I., Syberg S., Wang N., Robaye B., Gartland A., Jorgensen N., Arnett T., Boeynaems J. M., Bone phenotypes of P2 receptor knockout mice. Frontiers in Bioscience 2011 3 1038 1046 2-s2.0-79961007420
108. Ohlendorff S. D., Tofteng C. L., Jensen J. E. B., Petersen S., Civitelli R., Fenger M., Abrahamsen B., Hermann A. P., Eiken P., Jørgensen N. R., Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenetics and Genomics 2007 17 555 567 10.1097/FPC.0b013e3280951625 2-s2.0-34547925564 (Pubitemid 46905222)
109. Jørgensen N. R., Husted L. B., Skarratt K. K., Stokes L., Tofteng C. L., Kvist T., Jensen J. E. B., Eiken P., Brixen K., Fuller S., Clifton-Bligh R., Gartland A., Schwarz P., Langdahl B. L., Wiley J. S., Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. European Journal of Human Genetics 2012 20 675 681 2-s2.0-84856067474 10.1038/ejhg.2011.253
110. Gartland A., Skarratt K. K., Hocking L. J., Parsons C., Stokes L., Jørgensen N. R., Fraser W. D., Reid D. M., Gallagher J. A., Wiley J. S., Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. European Journal of Human Genetics 2012 20 5 559 564 2-s2.0-84859900260 10.1038/ejhg.2011.245
111. Wesselius A., Bours M. J. L., Agrawal A., Gartland A., Dagnelie P. C., Schwarz P., Jorgensen N. R., Role of purinergic receptor polymorphisms in human bone. Frontiers in Bioscience 2011 16 7 2572 2585 2-s2.0-79959546453 10.2741/3873
112. Wesselius A., Bours M. J. L., Henriksen Z., Association of P2X7 receptor polymorphisms with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Osteoporosis International 2013 24 1235 1246 10.1007/s00198-012-2059-x
113. Portales-Cervantes L., Niño-Moreno P., Doníz-Padilla L., Baranda-Candido L., García-Hernández M., Salgado-Bustamante M., González-Amaro R., Portales-Pérez D., Expression and function of the P2X7 purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Human Immunology 2010 71 8 818 825 2-s2.0-77954761646 10.1016/j.humimm.2010.05.008
114. Pelegrin P., Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7) receptor and Pannexin-1. Drug News & Perspectives 2008 21 8 424 433 10.1097/FPC.0b013e3280951625 2-s2.0-67649991492
115. Roger S., Pelegrin P., P2X7 receptor antagonism in the treatment of cancers. Expert Opinion on Investigational Drugs 2011 20 7 875 880 2-s2.0-79958798578 10.1517/13543784.2011.583918
116. Takenouchi T., Sekiyama K., Sekigawa A., Fujita M., Waragai M., Sugama S., Iwamaru Y., Kitani H., Hashimoto M., P2X7 Receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Archivum Immunologiae et Therapiae Experimentalis 2010 58 2 91 96 2-s2.0-77952746529 10.1007/s00005-010- 0069-y
117. Arulkumaran N., Unwin R. J., Tam F. W. K., A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opinion on Investigational Drugs 2011 20 7 897 915 2-s2.0-79958798010 10.1517/13543784.2011.578068
118. Baraldi P. G., Di Virgilio F., Romagnoli R., Agonists and antagonists acting at P2X7 receptor. Current Topics in Medicinal Chemistry 2004 4 16 1707 1717 2-s2.0-10644256586 10.2174/1568026043387223 (Pubitemid 39654456)
119. Romagnoli R., Baraldi P. G., Cruz-Lopez O., Lopez-Cara C., Preti D., Borea P. A., Gessi S., The P2X7 receptor as a therapeutic target. Expert Opinion on Therapeutic Targets 2008 12 5 647 661 2-s2.0-43349107705 10.1517/14728222.12.5.647 (Pubitemid 351699482)
120. Friedle S. A., Curet M. A., Watters J. J., Recent patents on novel p2x7 receptor antagonists and their potential for reducing central nervous system inflammation. Recent Patents on CNS Drug Discovery 2010 5 1 35 45 2-s2.0-77449148016 10.2174/157488910789753530
121. Keystone E. C., Wang M. M., Layton M., Hollis S., McInnes I. B., Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Annals of the Rheumatic Diseases 2012 71 1630 1635 2-s2.0-79952560339 10.1136/ard.2010.143578
122. Stock T. C., Bloom B. J., Wei N., Ishaq S., Park W., Wang X., Gupta P., Mebus C. A., Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. Journal of Rheumatology 2012 39 4 720 727 2-s2.0-84859456520 10.3899/jrheum.110874
123. Cruwys S., Midha A., Braddock M., Antagonism of the P2X7 receptor Attenuates Joint Destruction in a Model of Arthrites. ACR abstract poster 1772, 2007